Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences"

Axovant Gene Therapies Ltd (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the company will provide a corporate overview and participate in 1:1 meetings at upcoming virtual investor and patient conferences in September. Additionally, the company announced plans for their 1st Parkinson’s Disease R&D Day with key opinion leaders.

Investor and Patient Conference Presentation details:         

Baird Global Healthcare Conference
Date:	Wednesday, September 9, 2020
Time:	9:40 AM ET
2020 Virtual GM1 Family Meeting
Date:	Thursday, September 10, 2020
Time:	6:45 PM ET
Registration Link:	https://curegm1.org/2020-gm1-family-meeting-san-francisco/
Cantor Fitzgerald Virtual Global Healthcare Conference
Date:	Thursday, September 17, 2020
Time:	1:20 PM ET
Webcast link:	https://www.webcaster4.com/Webcast/Page/2495/37417
20th Annual Biotech in Europe Forum
Date:	Thursday, September 24, 2020
Time:	9:00 AM ET
Registration link:	https://www.sachsforum.com/20bef-registration.html
AXO-Lenti-PD Parkinson’s Disease R&D Day
Date:	Friday, October 30, 2020
Moderator:	Gavin Corcoran, MD, Chief R&D Officer, Axovant Gene Therapies
Additional details to be provided later in September.

A live webcast of the presentations will be available in the Events section of Axovant's website at www.axovant.com. A replay will be available for approximately 30 days following the conference.

About Axovant Gene Therapies

Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit www.axovant.com.

Contacts:

Media & Investors

Parag MeswaniAxovant Gene Therapies Ltd.(212) [e-mail]@axovant.com

Source: Axovant Gene Therapies